New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for H... ( HOERSHOLM Denmark an...)

HOME >> MEDICINE >> TECHNOLOGY

New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C

Date:12/3/2009

HOERSHOLM, Denmark and SAN DIEGO, California, December 3 /PRNewswire/ --

- SPC3649 Successfully Inhibits miR-122, a microRNA Important for Hepatitis C Viral Replication, Thereby Significantly Reducing Hepatitis C Virus in the Bloodstream in Chimpanzees Chronically Infected With the Hepatitis C Virus

- SPC3649 Demonstrates Efficacy With No Evidence of Viral Resistance and No Serious Adverse Events in the Treated Animals - Signaling a Potential Benefit for Patients Who are Not Responsive to or Cannot Tolerate Current Standard of Care Therapies

- SPC3649 is the First microRNA-Targeted Drug to Enter Human Clinical Trials; Phase 1 Clinical Trials Ongoing

- Santaris Pharma A/S Proprietary Locked Nucleic Acid (LNA) Drug Platform Fundamental in Developing Effective RNA-Targeted Therapies With High Affinity, Target Specificity and Remarkable Potency for a Range of Diseases

A study published online in this week's Science shows that SPC3649, a breakthrough microRNA-targeted therapy developed by Santaris Pharma A/S using its proprietary Locked Nucleic Acid (LNA) technology, holds promise as a novel treatment for patients infected with the Hepatitis C virus (HCV).

(Logo: http://www.newscom.com/cgi-bin/prnh/20090921/360545 )

The World Health Organization estimates about 3% of the world's population has been infected with HCV and that some 170 million are chronic carriers at risk of developing liver cirrhosis and/or liver cancer[1]. Approximately 3-4 million Americans are chronically infected with an estimated 40,000 new infections per year[2]. In Europe, there are about 4 million carriers[3].

Santaris Pharma A/S, the first company to have advanced both mRNA and microRNA targeted drugs into clinical trials, is an international biopharmaceutical c
'/>"/>

SOURCE Santaris Pharma A/S
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
2. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
3. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
6. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
7. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
8. Feeling Anxious or Distracted? New Research Shows a Cup of Tea Could Help
9. New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
10. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
11. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

Post Your Comments:

(Date:5/17/2013)... Conn. , May 17, 2013 /PRNewswire-iReach/ -- ... and recombinant proteins, is placing renewed emphasis on ... the rise as a number of factors are ... for pharmaceutical makers and their delivery device partners ... previously refractory conditions, the growing trend toward self-administration ...

(Date:5/17/2013)... MONTVALE, N.J. , May 17, 2013 /PRNewswire/ ... imaging, and Hitachi-Aloka Medical, a global leader in ... the two global companies to enable further innovation ... For years, the Hitachi-Aloka ultrasound systems and PENTAX ... world,s most trusted families of EUS systems. This ...

(Date:5/17/2013)... 2013 Sinovac Biotech Ltd. (Nasdaq: SVA ... , today announced that it will release its unaudited ... before market on Tuesday, May 28, 2013. The Company will ... 8:00 a.m. EDT (May 28, 2013 at 8:00 p.m. China ... an update on recent corporate developments. To access ...

Breaking Medicine Technology:Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 2 Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 3 PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems 2 PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems 3 Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 2 Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 3

[0] Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment [0] PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems [0] Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results

... InfuSystem Holdings, Inc. (NYSE Amex: INFU ) ... related services, today announced that the previously announced request ... Capital and certain affiliates (the "Kleinheinz Dissident Group") to ... valid based upon a report by an independent inspector ...

... Berg Biosystems and Berg Diagnostics, members of the Berg Pharma ... Spectrum Disorder (ASD) Biomarker Discovery Using the Berg Interrogative ... meeting in San Francisco, CA. The study was conducted by ... cases where more than 1 child was afflicted by the ...

Cached Medicine Technology:InfuSystem Provides Update on Special Meeting of Stockholders 2 Berg Pharma Companies Present Groundbreaking Approach to Understanding Autism and Identify Novel Biomarkers That May be Crucial in Diagnosis 2 Berg Pharma Companies Present Groundbreaking Approach to Understanding Autism and Identify Novel Biomarkers That May be Crucial in Diagnosis 3

InfuSystem Provides Update on Special Meeting of Stockholders Berg Pharma Companies Present Groundbreaking Approach to Understanding Autism and Identify Novel Biomarkers That May be Crucial in Diagnosis

(Date:5/20/2013)... 2013 Gerald Wojtala, executive director of ... at North Carolina Food Safety and Defense Task Force’s ... Need for Partnerships – from Farm to Fork – ... for May 22-23 at the Sheraton Imperial Hotel, will ... sector have in protecting the food supply. , Wojtala ...

(Date:5/19/2013)... The special introductory offer for the ... soon. "We are so excited to introduce our serum ... Beauty®. "It is a pleasure to use, it is ... also moisturizes the skin. One of the powerful ingredients ... is very successful in clinical studies." , Collagen makes ...

(Date:5/19/2013)... the heterogeneity the variety of genetic mutations of ... patients with the most common type of head and neck ... Cancer , investigators at Massachusetts General Hospital (MGH) and ... a better predictor of survival than most traditional risk factors ... of the head and neck. , "Our findings ...

(Date:5/19/2013)... Alonso Krangle LLP a dedicated law firm , ... on behalf of a-24-year-old financial analyst rendered quadriplegic as a ... accident lawsuit, which was filed in the Supreme Court for ... the property out as a bathing beach, but posted absolutely ... No. 34556/12) , According to the diving accident lawsuit complaint, ...

(Date:5/19/2013)... The three surgeons from the Center for ... Abrutyn, M.D., Robert S. Boretz, M.D., and Thomas J. ... current location, 215 Union Avenue, Suite B, Bridgewater, N.J. ... medicine, with emphasis on injuries of the knee and ... for a wide range of orthopedic problems. Dr. Abrutyn's ...

Breaking Medicine News(10 mins):Health News:IFPTI Executive Director to Speak at North Carolina Food Safety and Defense Task Force Annual Conference 2 Health News:Genetic diversity within tumors predicts outcome in head and neck cancer 2 Health News:Genetic diversity within tumors predicts outcome in head and neck cancer 3 Health News:Alonso Krangle Files Diving Accident Lawsuit on Behalf of Suffolk County Man Rendered Quadraplegic in Tragic Diving Accident at Long Island Beach 2 Health News:Alonso Krangle Files Diving Accident Lawsuit on Behalf of Suffolk County Man Rendered Quadraplegic in Tragic Diving Accident at Long Island Beach 3 Health News:Summit Medical Group Welcomes the Center for Orthopedic Care 2 Health News:Summit Medical Group Welcomes the Center for Orthopedic Care 3

[0] IFPTI Executive Director to Speak at North Carolina Food Safety and Defense Task Force Annual Conference [0] Collagen is a Key Anti-Aging Ingredient and is Featured in the New Collagen Peptide Serum at Sublime Beauty®; Introductory Offer on Now [0] Genetic diversity within tumors predicts outcome in head and neck cancer [0] Alonso Krangle Files Diving Accident Lawsuit on Behalf of Suffolk County Man Rendered Quadraplegic in Tragic Diving Accident at Long Island Beach [0] Summit Medical Group Welcomes the Center for Orthopedic Care

... business with the independence and sustainability to deliver significant improvements ... on HIV with industry-leading pipeline to deliver more new HIV ... Pfizer , LONDON and PHILADELPHIA, April 16 GlaxoSmithKline plc ... PFE ) today announced they have entered into an ...

... April 16, 2009) NEW YORK, April 16 A rich ... in the New York area received a comprehensive voice check-up ... at the second annual free Voice Screening for Professional Singers, ... Infirmary and MusiCares, the charitable arm of the ...

... MONTREAL, April 16 Messaging Architects ( ... email security and compliance, will present its latest ... RSA Conference (April 19-24), the world,s premier information ... consistently attracts the industry,s leading providers of email ...

... month , ... Raleigh and Rocky Mount, N.C. (PRWEB) April 16, 2009 ... is pleased to announce the launch of the 2009 HensonFuerst Health Initiative, ... service efforts. The initiative was developed as a way to encourage both ...

... /PRNewswire-Asia-FirstCall/ -- SOKO Fitness & Spa,Group, Inc. (OTC Bulletin ... in Northern China, announced its operating results for the ... Total revenue for the quarter was $5.1 ... the previous year. For the nine months ended February ...

... saving lives, the MedicAlert Foundation partners with Thrive ... medical information in an emergencyTURLOCK, Calif., April 15 ... in providing emergency response medical information services, today ... Allergy & Gluten-free Expo in 2009, taking place ...

GlaxoSmithKline and Pfizer Announce Innovative Agreement to Create a New World-Leading, Specialist HIV Company Singers Hit High Notes in Free Voice Screening at The New York Eye and Ear Infirmary Comprehensive Email Lifecycle Management Focus for Messaging Architects at RSA Conference HensonFuerst Announces Year-Round Community Program SOKO Fitness & Spa Group Announces Third Quarter FY2009 Financial Results MedicAlert Brings History of Saving Lives to Chicago for Inaugural Thrive Allergy & Gluten-free Expo

... The Vitros 250 is a ... requirements in multiple environments ... hospitals, clinics and satellite locations. ... on-board dilution, and can be ...

AxSYM Plus provides cutting-edge ergonomics and smart new features that mean increased ease-of-use and enhanced reliability. Also, advanced software means less operator intervention and high-integrit...

The ADx system uses fluorescence polarization immunoassay technology for the detection of abused drugs and toxicology assays....

The UniCel DxI 800 with its exceptional throughput, proven chemiluminescent technology, assay protocols like Access, Access 2, Synchron LXi 725 and load "on-the-fly" capability simplifies and automat...

Medicine Products:

Vitros 250 Chemistry System AxSYM Plus ADx System UniCel DxI 800